Castle Biosciences (CSTL) Forward P/S Multiple

Castle Biosciences attracts leading geneticists and oncologists by leveraging academic prestige and stock option programs. The forward P/S indicator visualizes the objective price action of the asset relative to future sales, where the value of 2.80 reflects the metric's balance. The integration of tests into medical standards ensures a steady cash flow. The company's environmental profile is minimal and limited to the digitalization of document workflows.

CSTL castlebiosciences.com: Market Cap to Expected Sales Ratio in the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Castle Bio (CSTL)

- market price and analyst price targets:

Price Chart Castle Biosciences, Inc.|CSTL - Analyst Median Target

- market capitalization details:

Market Capitalization Castle Bio|CSTL - Company Buyout Price

- issuer book value statistics:

Net Assets per Single Share Castle Biosciences|CSTL - Book Valuation of Business|Market Capitalization to Book Value Ratio castlebiosciences.com|CSTL - Cumulative Company Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

CSTL - Company Net Income|Future Profit Castle Biosciences|CSTL - Company Value to Net Income|Forward P/E Multiple Castle Biosciences Corp|CSTL - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Castle Bio|CSTL - Operating income before deduction of amortization|Earnings per share for the last twelve months Castle Biosciences|CSTL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months castlebiosciences.com|CSTL - Expected net earnings per share growth this year|Earnings growth forecast for next year Castle Biosciences

- sales volume and revenue indicators:

CSTL - Company Sales|Projected Sales Volume Castle Biosciences, Inc.|CSTL - Price-to-Revenue Coefficient|Forward P/S Multiple Castle Bio

Comprehensive company analysis:Castle Biosciences, Inc. (CSTL)

Investors view Castle Biosciences (CSTL) as a high-growth asset driven by the expansion of its diagnostic panels. This metric compares the business's market value with projected sales volume to determine the extent to which future revenues are currently priced in. By analyzing the projected price-to-sales ratio, one can assess the monetization efficiency of the R&D pipeline in dermato-oncology. This security is classified as a high-tech asset with a pronounced innovation premium.

Competing companies

Price-to-Projected Revenue Ratio Caris Life Sciences CAI|Market Cap to Expected Sales Ratio Guardant Health Inc (GH)|Veracyte Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Celcuity Therapeutics CELC|GRAIL, Inc. (GRAL) - Price-to-Projected Revenue Ratio|MYGN - Market Cap to Expected Sales Ratio|BNR (Burning Rock) - Forward P/S Multiple|Forward Price-to-Revenue Multiple VolitionRx Ltd (VNRX)|Forward P/S Multiple BDSX|Forward P/S Multiple Precipio Inc (PRPO)|Price-to-Projected Revenue Ratio Check-Cap CHEK|Market Cap to Expected Sales Ratio Mainz Biomed NV (MYNZ)|OCX: Forward Price-to-Revenue Multiple